942215-52-3Relevant academic research and scientific papers
2-Arylbenzoxazoles as CETP inhibitors: Raising HDL-C in cynoCETP transgenic mice
Kallashi, Florida,Kim, Dooseop,Kowalchick, Jennifer,Park, You Jung,Hunt, Julianne A.,Ali, Amjad,Smith, Cameron J.,Hammond, Milton L.,Pivnichny, James V.,Tong, Xinchun,Xu, Suoyu S.,Anderson, Matt S.,Chen, Ying,Eveland, Suzanne S.,Guo, Qiu,Hyland, Sheryl A.,Milot, Denise P.,Cumiskey, Anne-Marie,Latham, Melanie,Peterson, Laurence B.,Rosa, Raymond,Sparrow, Carl P.,Wright, Samuel D.,Sinclair, Peter J.
, p. 558 - 561 (2011/03/17)
We describe structure-activity studies leading to the discovery of 2-arylbenzoxazole 3, the first in a series to raise serum high-density lipoprotein cholesterol levels in transgenic mice. Replacement of the 4-piperidinyloxy moiety with piperazinyl provid
CETP INHIBITORS
-
Page/Page column 39, (2008/06/13)
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I
